Full Text View
Tabular View
No Study Results Posted
Related Studies
Multicenter, Predictive, Prospective, Phase III, Open, Randomized, Pharmacogenomic Study in Patients With Advanced Lung Carcinoma (BREC)
This study is currently recruiting participants.
Verified December 2011 by Spanish Lung Cancer Group
Study NCT00617656   Information provided by Spanish Lung Cancer Group

First Received on February 5, 2008.   Last Updated on February 14, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
LUNG CANCER
Additional conditions recognized in this trial
Lung Neoplasms
More general conditions related to this trial
Lung Diseases
Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Interventions listed in this trial
Cisplatin, Docetaxel
Gemcitabine, Cisplatin
Docetaxel, Cisplatin
Docetaxel
Additional drug interventions recognized in this trial
Cisplatin
Gemcitabine
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
Spanish Lung Cancer Group


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services